Recombinant Human Protein Kinase C Eta Type (PRKCH) Protein (His)

Name: Recombinant Human Protein Kinase C Eta Type (PRKCH) Protein (His)
Brand: Beta LifeScience
SKU: BLC-00293P
Availability: InStock

Greater than 90% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Protein Kinase C Eta Type (PRKCH) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 90% as determined by SDS-PAGE.
Uniprotkb	P24723
Target Symbol	PRKCH
Species	Homo sapiens (Human)
Expression System	E.coli
Tag	C-6His
Target Protein Sequence	MSSGTMKFNGYLRVRIGEAVGLQPTRWSLRHSLFKKGHQLLDPYLTVSVDQVRVGQTSTKQKTNKPTYNEEFCANVTDGGHLELAVFHETPLGYDHFVANCTLQFQELLRTTGASDTFEGWVDLEPEGKVFVVITLTGSFTEATLQRDRIFKHFTRKRQRAMRRRVHQINGHKFMATYLRQPTYCSHCREFIWGVFGKQGYQCQVCTCVVHKRCHHLIVTACTCQNNINKVDSKIAEQRFGINIPHKFSIHNYKVPTFCDHCGSLLWGIMRQGLQCKICKMNVHIRCQANVAPNCGVNAVELAKTLAGMGLQPGNISPTSKLVSRSTLRRQGKESSKEGNGIGVNSSNRLGIDNFEFIRVLGKGSFGKVMLARVKETGDLYAVKVLKKDVILQDDDVECTMTEKRILSLARNHPFLTQLFCCFQTPDRLFFVMEFVNGGDLMFHIQKSRRFDEARARFYAAEIISALMFLHDKGIIYRDLKLDNVLLDHEGHCKLADFGMCKEGICNGVTTATFCGTPDYIAPEILQEMLYGPAVDWWAMGVLLYEMLCGHAPFEAENEDDLFEAILNDEVVYPTWLHEDATGILKSFMTKNPTMRLGSLTQGGEHAILRHPFFKEIDWAQLNHRQIEPPFRPRIKSREDVSNFDPDFIKEEPVLTPIDEGHLPMINQDEFRNFSYVSPELQP
Expression Range	1-683aa
Protein Length	Full Length
Mol. Weight	84.7 kDa
Research Area	Metabolism
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	Calcium-independent, phospholipid- and diacylglycerol (DAG)-dependent serine/threonine-protein kinase that is involved in the regulation of cell differentiation in keratinocytes and pre-B cell receptor, mediates regulation of epithelial tight junction integrity and foam cell formation, and is required for glioblastoma proliferation and apoptosis prevention in MCF-7 cells. In keratinocytes, binds and activates the tyrosine kinase FYN, which in turn blocks epidermal growth factor receptor (EGFR) signaling and leads to keratinocyte growth arrest and differentiation. Associates with the cyclin CCNE1-CDK2-CDKN1B complex and inhibits CDK2 kinase activity, leading to RB1 dephosphorylation and thereby G1 arrest in keratinocytes. In association with RALA activates actin depolymerization, which is necessary for keratinocyte differentiation. In the pre-B cell receptor signaling, functions downstream of BLNK by up-regulating IRF4, which in turn activates L chain gene rearrangement. Regulates epithelial tight junctions (TJs) by phosphorylating occludin (OCLN) on threonine residues, which is necessary for the assembly and maintenance of TJs. In association with PLD2 and via TLR4 signaling, is involved in lipopolysaccharide (LPS)-induced RGS2 down-regulation and foam cell formation. Upon PMA stimulation, mediates glioblastoma cell proliferation by activating the mTOR pathway, the PI3K/AKT pathway and the ERK1-dependent phosphorylation of ELK1. Involved in the protection of glioblastoma cells from irradiation-induced apoptosis by preventing caspase-9 activation. In camptothecin-treated MCF-7 cells, regulates NF-kappa-B upstream signaling by activating IKBKB, and confers protection against DNA damage-induced apoptosis. Promotes oncogenic functions of ATF2 in the nucleus while blocking its apoptotic function at mitochondria. Phosphorylates ATF2 which promotes its nuclear retention and transcriptional activity and negatively regulates its mitochondrial localization.
Subcellular Location	Cytoplasm.
Protein Families	Protein kinase superfamily, AGC Ser/Thr protein kinase family, PKC subfamily
Database References	HGNC: 9403 OMIM: 601367 KEGG: hsa:5583 STRING: 9606.ENSP00000329127 UniGene: PMID: 28939105 PRKCH rs2230500 gene polymorphism is significantly related to the efficiency in telmisartan therapy (p = 0.02). The PRKCH rs2230500 may influence the antihypertensive efficacy of telmisartan in Chinese EH patients. PMID: 28640647 PRKCH is highly expressed in hematopoietic stem cell (HSC) and is necessary for optimal HSC function. PMID: 28596089 The association between PRKCH 1425G/A and lacunar infarction was independent of traditional stroke risk factors PMID: 25900926 variant genotypes of PRKCH 1425G/A are an independent prognostic factor for ischemic stroke in the final multivariate Cox regression model PMID: 25370935 Meta-analysis indicated that the 1425G/A SNP in PRKCH may contribute to susceptibility of stroke, especially for ischemic stroke. PMID: 25272991 PKCeta promotes senescence through its ability to upregulate the expression of the cell cycle inhibitors p21Cip1 and p27Kip1 and enhance transcription and secretion of IL-6. PMID: 25412309 The 1425G/A polymorphism in PRKCH is not a significant predictor of stroke recurrence in patients with acute ischemic stroke during a 2-year follow-up period. PMID: 24534126 PKC-eta associates with NHE3 and gamma tubulin to promote the cell polarity during migration. PMID: 24788043 These results suggest that siRNA-mediated silencing of PKCeta can be a potent tool to complement existing chemotherapy regimens for treating EBV(+) B lymphoma. PMID: 24784886 the PKC family genes may play a role in the pathogenesis of MS relapse through modulating the association between 25(OH)D and relapse. PMID: 23868949 study demonstrates that type V collagen induces the down-regulation of protein kinase C eta PMID: 22213077 these results suggest that the regulation of PKCeta is unique and PKCepsilon is required for the PKC activator-induced upregulation of PKCeta. PMID: 22892130 The single nucleotide polymorphism (rs2230500) in PRKCH decreases the risk of carotid intima-media thickness. PMID: 22808203 There was loss of the negative correlation in the expression levels of CD3eta and FcepsilonRIgamma genes in CLL patients. PMID: 22664044 Protein kinase Ceta 1425G/A variant was not a risk locus for deep intracerebral hemorrhage phenotype. PMID: 22999931 It was shown that the PKCeta isoform is a negative regulator of the AKT signaling pathway. The IGF-I induced phosphorylation on Ser473 of AKT was inhibited by the PKCeta-induced expression in MCF-7 breast adenocarcinoma cancer cells. PMID: 22305966 A remarkable association of minor alleles (1425G/A and _15) in the PRKCH gene with an elevated risk of coronary artery disease and increased levels of LDL-C in a Chinese population. PMID: 21625852 The present meta-analyses suggested that 1425G/A SNP in PRKCH was associated with ischemic stroke, particularly lacunar infarction, in Chinese and Japanese populations. PMID: 22044875 In the present study, a significant association between the PRKCH 1425G/A polymorphism and SSNHL risk was observed through a nested case-control analysis within the population-based study. PMID: 21756056 study suggests that PKCeta is involved in NF-kappaB signaling leading to drug resistance. PMID: 21820409 Catalytic activity of protein kinase C eta (PKCeta) is not necessary for enlarged and flattened morphology of differentiated human keratinocytes, although it is important for gene expression of the marker proteins. PMID: 21346190 the AA genotype of PRKCH, relative to the G/G genotype, may be a higher risk genotype for severe gastric atrophy PMID: 20602195 Reduced expression of PKCeta may represent a molecular lesion in the development of more aggressive disease of human hepatocellular carcinoma. PMID: 20001341 that PKC eta negatively regulates UV-induced apoptosis through its localization, resistance to cleavage, and the p38 MAPK pathway PMID: 12646210 Minute virus of mice infection causes accumulation of endogenous PKCeta in the nuclear periphery and regulaties this NS1 regulating kinase, thus underlining the tight interconnection between PKC-mediated signaling and the parvoviral life cycle PMID: 12829844 The major result is a clear correlation of PKC eta expression with tumor progression in renal cell carcinoma. PMID: 14666709 There was expression of protein kinase C eta in abnormal muscle fibers. Protein kinase C isoforms may play a role in the pathogenesis of myofibrillar myopathy. PMID: 15159477 PKC-eta targets the Akt and mTOR signaling pathways PMID: 15489897 These studies demonstrate translocation of PKCeta to the nuclear envelope, and suggest that the spatial regulation of PKCeta could be important for its cellular functions including effects on cell cycle control and involvement in tumor promotion. PMID: 16242915 PKC-eta-mediated glioblastoma proliferation involves MEK/mitogen-activated protein (MAP) kinase phosphorylation, activation of ERK and subsequently of Elk-1. PMID: 17146445 Our results provide evidence of the involvement of PRKCH as a susceptibility gene for rheumatoid arthritis in the Japanese population PMID: 17195206 Fission of transport carriers at the trans-Golgi network is dependent on specifically PLCbeta3, which is necessary to activate PKCeta and PKD in that Golgi compartment, via diacylglycerol production. PMID: 17492941 PKCeta functions as an anti-apoptotic protein in Hodgkin's lymphoma-derived cell lines PMID: 17786031 PRKCH mRNA was expressed at lower level in rheumatoid arthritis unrelated patients than in healthy controls, and is not a rheumatoid arthritis major susceptibility genetic factor in the French Caucasian population. PMID: 17957454 PRKCH gene polymorphisms have a role in subcortical silent brain infarction PMID: 18164711 Results establish PKCeta as a unique element in interferon signaling that plays a key and essential role in the generation of the regulatory effects of type I IFNs on normal and leukemic hematopoiesis. PMID: 19211565 nPKCeta positively regulates agonist-induced thromboxane generation with no effects on platelet aggregation. PMID: 19286657 The 1425G/A SNP in PRKCH increases the risk of both ischemic stroke and cerebral hemorrhage in the Chinese population. PMID: 19520989 Data show that PKCeta is an anti-apoptotic protein, acting as a negative regulator of JNK activity. PMID: 19523467 Translational regulation could provide an additional level for controlling the expression of PKC family members. PMID: 19797084 We report that a nonsynonymous SNP in PRKCH increases the risk of cerebral infarction in the general Japanese population. We also found that PKCeta was expressed in vascular endothelial cells and foamy macrophages in human atherosclerotic lesions. PMID: 17206144

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.